EUROIMMUN is one of the leading manufacturers of medical laboratory diagnostics worldwide and stands for innovation. Around 2000 employees in twelve countries develop, produce and sell test systems for the diagnosis of diseases, and software and automation solutions for the performance and evaluation of these assays.

Laboratories in over 150 countries use EUROIMMUN products for the diagnosis of autoimmune, infectious diseases and allergies, and to perform genetic analyses. The company was founded 1987 from the University of Luebeck (Schleswig-Holstein, Germany). In the business year 2014, the group turnover amounted to 175 million euros.

The enterprise has extensive expertise in the fields of immunology, cell biology, histology, biochemistry and molecular biology. EUROIMMUN is based on state-of-the-art, partly patented production processes and microanalysis techniques.

Among the initial pioneer achievements of the company was the development of the BIOCHIP (1983). Today, EUROIMMUN has at its disposal virtually fully automated BIOCHIP fragmentation and production devices, which were designed and produced in-house and are now in use worldwide.

Furthermore, EUROIMMUN commands a broad technology base which has enabled it to initiate and promote fundamental, new developments in medical laboratory diagnostics. Examples are the molecular biological synthesis of designer antigens, computer-aided immunofluorescence microscopy (CAIFM) and the development of multi-parametric microarrays for the identification of genetic polymorphisms, tumours or pathogenic agents, amongst others.

Great expertise and ongoing training are essential for the use and distribution of the products. Every year, the EUROIMMUN Academy receives almost 1000 customers from over 50 countries, providing training for customers, field staff, and employees from all EUROIMMUN subsidiaries. The accredited Institute for Quality Assurance, an institution of the company, organises quality assessment schemes and thus helps to maintain the high quality standard of external laboratories.

The Institute for Experimental Immunology, another EUROIMMUN institution, is dedicated to basic research. The institute also cooperates with universities, clinics and renowned research institutions from all over the world. These cooperations have resulted in a large number of diploma and doctorate theses. EUROIMMUN is ISO certified (EN ISO 9001:2008, EN ISO 13485:2012, ISO 13485/CMDCAS).

A large share of the company’s success can be attributed to the associated reference laboratory, which offers a fast and differentiated diagnosis to the EUROIMMUN customers and clarifies several hundreds of patient samples with difficult constellations every day.

EUROIMMUN meets its needs for qualified personnel not only through its presence at recruitment and trade fairs and advertisement, but also through its own training program. Alongside the vocational school, the apprentices and trainees are offered a comprehensive practical and theoretical program and intensive mentoring in the work routine.

At present, the company employs 60 trainees and around 2000 persons worldwide. Women represent nearly 60% of staff and thus the majority. 912 employees have an academic background, 134 of them hold a doctoral degree.

The atmosphere in the company is productive and characterised by openness and mutual respect. EUROIMMUN offers unlimited employment contracts. All employees
can participate in the company’s success as shareholders, benefit from the company’s pension scheme, receive bonuses for excellent performance, and have the possibility to participate in regular trainings. The company’s restaurant offers an excellent choice of food. Day care and an after-school club is provided for the employees’ children.

EUROIMMUN in figures

<table>
<thead>
<tr>
<th>Year</th>
<th>Event/Number</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1987</td>
<td>founded</td>
<td>in Luebeck, Germany</td>
</tr>
<tr>
<td>175 M</td>
<td>euros annual Group turnover in 2014</td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td>employees worldwide</td>
<td></td>
</tr>
<tr>
<td>912</td>
<td>university graduates</td>
<td></td>
</tr>
<tr>
<td>134</td>
<td>employees with doctoral degree</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>apprentices</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>offices in Germany</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>subsidiaries in other countries</td>
<td></td>
</tr>
<tr>
<td>176</td>
<td>proprietary/in-licensed IP rights</td>
<td></td>
</tr>
</tbody>
</table>
|       | “Most Innovative Medium-Sized Businesses in Germany” | (WirtschaftsWoche, April 2014)

Recent product innovations

- **Anti-PLA2R ELISA**: Quantitative detection of autoantibodies against phospholipase A2 receptor (PLA2R) in primary membranous glomerulonephritis (MGN)
- **Anti-Echinococcus ELISA**: Semiquantitative diagnosis of infections with Echinococcus granulosus as well as Echinococcus multilocularis by the use of native, purified Echinococcus multilocularis vesicular fluid (EmVF)
- **CXCL13 ELISA**: Diagnosis and therapy monitoring of neuroborreliosis. First assay worldwide for the quantification of CXCL13 in cerebrospinal liquid to be approved for in vitro diagnostics
- **DPA-Dx Profiles Pollen, Insect Venoms, Paediatrics**: Molecular allergy diagnostics based on individually purified allergen components (defined partial allergens, DPA) for differential diagnosis of allergic sensitisation patterns
- **EUROArray HPV**: Molecular diagnosis of infections for detection and typing of 30 anogenital HPV types (18 high-risk and 12 low-risk HPV) in a single reaction
- **EUROPATTERN Microscope and software**: Automated microscopy and modern interpretation of diagnostic results at the PC screen (ANA, ANCA, Crithidia, tissue, EUROPLUS – also in mosaics) and pattern recognition with titer determination
- **Dengue Virus NS1 ELISA**: Detection of viral protein NS1 as early marker of an acute infection. Reliable diagnosis in all stages of the disease, exclusion of cross reactions with anti-flavivirus antibodies and differential diagnosis of tropical diseases
- **EUROBLOTone**: Complete automation solution for the immunoblot workstation – from sample pipetting to the final result
Publications with EUROIMMUN’s participation (2015)

Publications


**Scientific presentations**


12. Stöcker W. Comprehensive diagnostics of neurology-related autoantibodies using authentic recombinant autoantigens. All-Russia XX Conference on Neuroimmunology, Multiple Sclerosis, St. Petersburg, Russia (2015).


14. Stöcker W. Revealing new forms of autoimmune encephalitis associated with autoantibodies against neuron specific Na/K-ATPase ATP1A3, neurochondrin, flotillin and inositoltriphosphate-receptors. Oral presentation at the Beijing Union Medical College Hospital, Beijing, China (2015).

New patents


